Lexaria Bioscience (LEXX) Return on Equity (2017 - 2026)

Lexaria Bioscience has disclosed Return on Equity across 10 years of filings, most recently posting 0.02% for Q1 2026.

• Return on Equity for Q1 2026 came in at 0.02%, down 1.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 0.02% (down 1.0% YoY), and the FY2025 annual result was 0.02%, down 1.0% from the prior year.
• Return on Equity came in at 0.02% for Q1 2026 at Lexaria Bioscience, up from 0.03% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.0% in Q1 2022 to a low of 0.03% in Q3 2025.
• The 5-year median for Return on Equity is 0.01% (2025), against an average of 0.01%.
• Across the five-year window, Return on Equity grew 1 bps in 2024 and slipped 2 bps in 2025, its largest moves.
• Lexaria Bioscience's Return on Equity stood at 0.01% in 2022, then slumped by 112 bps to 0.02% in 2023, then surged by 57 bps to 0.01% in 2024, then plunged by 235 bps to 0.03% in 2025, then jumped by 41 bps to 0.02% in 2026.
• The last three Return on Equity figures came in at 0.02% (Q1 2026), 0.03% (Q4 2025), and 0.03% (Q3 2025), per Business Quant data.